ALPS Medical Breakthroughs ETF
Filed by Alps ETF Trust. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| ACADACADIA Pharmaceuticals Inc | 2.54% | $6.1M |
| RLAYRelay Therapeutics Inc | 2.05% | $4.9M |
| AMLXAmylyx Pharmaceuticals Inc | 1.93% | $4.6M |
| GPCRStructure Therapeutics Inc | 1.68% | $4M |
| BCRXBioCryst Pharmaceuticals Inc | 1.27% | $3M |
| NKTRNektar Therapeutics | 1.24% | $3M |
| SRPTSarepta Therapeutics Inc | 1.14% | $2.7M |
| AGIOAgios Pharmaceuticals Inc | 1.03% | $2.5M |
| CMPSCompass Pathways PLC | 0.94% | $2.2M |
| KURAKura Oncology Inc | 0.58% | $1.4M |
| DCTHDelcath Systems Inc | 0.29% | $703.4K |
| TECXTectonic Therapeutic, Inc. - Common Stock | 0.29% | $699.4K |
| RLMDRelmada Therapeutics Inc | 0.24% | $565.9K |
| ENTAEnanta Pharmaceuticals Inc | 0.20% | $479.6K |
| AVXLAnavex Life Sciences Corp | 0.13% | $321.1K |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow ALPS Medical Breakthroughs ETF by email
ALPS Medical Breakthroughs ETF's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.